OTCMKTS:ADDXF - Addex Therapeutics Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 06/14/2019 04:00 PM ET)
Today's Range
Now: $1.54
50-Day Range
MA: $1.90
52-Week Range
Now: $1.54
Average Volume350 shs
Market Capitalization$23.92 million
P/E RatioN/A
Dividend YieldN/A
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for the treatment of human health. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149 for epilepsy and an undisclosed central nervous system disorders; and ADX71441 for the treatment of Charcot-Marie-Tooth type 1A neuropathy and addiction. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual SalesN/A



Market Cap$23.92 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ADDXF News and Ratings via Email

Sign-up to receive the latest news and ratings for ADDXF and its competitors with MarketBeat's FREE daily newsletter.

Addex Therapeutics (OTCMKTS:ADDXF) Frequently Asked Questions

What is Addex Therapeutics' stock symbol?

Addex Therapeutics trades on the OTCMKTS under the ticker symbol "ADDXF."

Has Addex Therapeutics been receiving favorable news coverage?

Headlines about ADDXF stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Addex Therapeutics earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the next few days. View News Stories for Addex Therapeutics.

Who are some of Addex Therapeutics' key competitors?

What other stocks do shareholders of Addex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addex Therapeutics investors own include Syncona (SYNC), Omega Diagnostics Group (ODX), Indivior (INDV), Evonik Industries (EVK), Bayer (BAYN), MediGene (MDG1), Lanxess (LXS), Fresenius Medical Care AG & Co. KGaA (FME), Evotec (EVT) and Covestro (1COV).

Who are Addex Therapeutics' key executives?

Addex Therapeutics' management team includes the folowing people:
  • Mr. Timothy Dyer, Co-Founder, CEO & Director (Age 51)
  • Dr. Roger G. Mills, Chief Medical Officer & Director (Age 62)
  • Dr. Jean-Philippe Rocher, Co-Head of Discovery & Member of the Exec. Management (Age 60)
  • Dr. Robert Lütjens, Head of Discovery (Age 51)
  • Dr. Bruno Bournique, Head of Absorption, Distribution, Metabolism and Excretion (ADME) / Pharmacokinetics (PK)

How do I buy shares of Addex Therapeutics?

Shares of ADDXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Addex Therapeutics' stock price today?

One share of ADDXF stock can currently be purchased for approximately $1.54.

How big of a company is Addex Therapeutics?

Addex Therapeutics has a market capitalization of $23.92 million. View Additional Information About Addex Therapeutics.

MarketBeat Community Rating for Addex Therapeutics (OTCMKTS ADDXF)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Addex Therapeutics and other stocks. Vote "Outperform" if you believe ADDXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADDXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/15/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel